Ftse Mib
36.147,06
-0,12%
DAX
21.430,58
0,71%
S&P 500
6.067,70
0,92%
NASDAQ
19.733,59
2,03%
Bitcoin
102.013,38
0,67%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Syndax Pharmaceuticals Inc (SNDX) Syndax Pharmaceuticals Inc (SNDX) Notizie

Syndax Pharmaceuticals Inc

SNDX
14,36
0,08 (0,56%)
29 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/1/202523:50EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
15/1/202523:34PRNUSIncyte and Syndax Announce U.S. Food and Drug Administration..
13/1/202513:00PRNUSSyndax Highlights Recent Accomplishments and Anticipated..
08/1/202503:20PRNUSKuehn Law Encourages Investors of Syndax Pharmaceuticals,..
07/1/202513:00PRNUSSyndax Announces Presentation at 43rd Annual J.P. Morgan..
03/1/202522:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
20/12/202423:00EDGAR2Form 8-K - Current report
09/12/202413:30PRNUSSyndax Announces Additional Positive Data for Revuforj®..
08/12/202400:15PRNUSSyndax Presents Positive Revuforj® (revumenib) Data in Acute..
06/12/202422:28EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
03/12/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
27/11/202413:00PRNUSSyndax Announces Participation at the Citi 2024 Global..
15/11/202423:29PRNUSSyndax Announces FDA Approval of Revuforj® (revumenib), the..
12/11/202413:05EDGAR2Form 8-K - Current report
12/11/202413:00PRNUSSyndax Announces Positive Pivotal Topline Results from..
05/11/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/11/202422:02EDGAR2Form 8-K - Current report
05/11/202422:01PRNUSSyndax Reports Third Quarter 2024 Financial Results and..
05/11/202415:01PRNUSSyndax to Host ASH Investor Event in Person and via Webcast..
05/11/202415:00PRNUSSyndax Announces Revumenib Abstracts to Be Presented at the..
04/11/202422:01PRNUSSyndax Pharmaceuticals and Royalty Pharma Enter into $350..
01/11/202421:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
01/11/202412:00PRNUSSyndax Announces Participation in November Investor..
29/10/202412:00PRNUSSyndax to Announce Third Quarter 2024 Financial Results and..
04/10/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
18/9/202423:15PRNUSIncyte and Syndax Announce New England Journal of Medicine..
06/9/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
15/8/202422:15BWIncyte und Syndax melden FDA-Zulassung von Niktimvo™..
15/8/202412:26BWIncyte et Syndax annoncent l’approbation par la FDA..
14/8/202423:34BWIncyte and Syndax Announce U.S. FDA Approval of Niktimvo™..
12/8/202413:00PRNUSSyndax Announces Publication in the Journal of Clinical..
05/8/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
01/8/202422:05PRNUSSyndax Reports Second Quarter 2024 Financial Results and..
01/8/202422:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202422:02EDGAR2Form 8-K - Current report
29/7/202413:01PRNUSSyndax Announces PDUFA Action Date Extension for Revumenib..
25/7/202413:00PRNUSSyndax to Announce Second Quarter 2024 Financial Results and..
05/7/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
17/6/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202413:00PRNUSSyndax Presents Updated Positive Data from BEAT AML and..
10/6/202413:30GLOBEPyxis Oncology Expands Board of Directors with Appointment..
06/6/202413:00PRNUSSyndax Announces Plans to Advance into Phase 1b Portion of..
05/6/202413:00PRNUSSyndax Announces Participation at the Goldman Sachs 45th..
03/6/202422:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
16/5/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
15/5/202422:11EDGAR2Form 8-K - Current report
15/5/202422:05PRNUSSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D...
09/5/202413:00PRNUSSyndax Announces Participation at the Bank of America..
08/5/202413:06PRNUSSyndax Pharmaceuticals Reports First Quarter 2024 Financial..
Apertura: 14,16 Min: 14,01 Max: 14,71
Chiusura: 14,28

La tua Cronologia

NASDAQ
SNDX
Syndax Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network